Cost-effectiveness of combination peginterferon α-2a and ribavirin compared with interferon α-2b and ribavirin in patients with chronic hepatitis C

American Journal of Gastroenterology

Volumn 99, Issue 8, 2004, Pages 1490-1496

  Sullivan, Sean D ^a   Jensen, D M ^b   Bernstein, D E ^b   Hassanein, T I ^b   Foster, G R ^b   Lee, S S ^b   Cheinquer, H ^b   Craxi, A ^b   Cooksley, Graham ^b   Klaskala, W ^b   Pettit, K ^b   Patel, K K ^b   Green, J ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ARTICLE; CHRONIC HEPATITIS; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; GENOTYPE; HEPATITIS C; HUMAN; LIFE EXPECTANCY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE;

ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; GENOTYPE; HEALTH CARE COSTS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; POLYETHYLENE GLYCOLS; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS; RIBAVIRIN; UNITED STATES; VIRAL LOAD;

EID: 4444288448     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2004.30286.x     Document Type: Article

References (35)

1. Global surveillance and control of Hepatitis C. Report of a WHO consultation. J Viral Hepat 1999;6:35-47.
2. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1998 through 1994. N Engl J Med 1999;341:556-62.
3. Williams I. Epidemiology of hepatitis C in the United States. Am J Med 1999;107:2S-9S.
4. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002;36:S35-S46.
5. Kiyosawa K, Sodeyama T, Tanaka E, et al. Interrelationship of blood transfusion, NANB hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virus. Hepatology 1990;12:671-75.
6. Tong MJ, El-Farra NS, Reikes AR, et al. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995;332:1463-66.
7. Yano M, Kumada H, Kage M, et al. The long-term pathological evolution of chronic hepatitis C. Hepatology 1996;23:1334-40.
8. Gordon SC, Eloway RS, Long JC, et al. The pathology of hepatitis C as a function of mode of transmission: Blood transfusion versus intravenous drug abuse. Hepatology 1993;18:1338-43.
9. Niederau C, Lange S, Heintges T, et al. Prognosis of chronic hepatitis C: Results of a large, prospective cohort study. Hepatology 1998;28:1687-95.
10. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002. Hepatology 2002;36:S3-S20.
11. Buti M, Casado MA, Fosbrook L, et al. Cost-effectiveness of combination therapy for naïve patients with chronic hepatitis C. J Hepatol 2000;33:651-8.
12. Sullivan SD, Green J, Patel KK, et al. A comparison of cost-effectiveness of peginterferon alfa-2a (PEGASYS) plus ribavirin (40KD) (COPEGUS) vs interferon alfa-2b plus ribavirin as first treatment of chronic hepatitis C (CHC). J Hepatol 2003;38(suppl 2):174.
13. Siebert U, Sroczynski G, Rossol S, et al. Cost-effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 2003;52:425-32.
14. Buti M, Medina M, Casado A, et al. A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naïve patients with chronic hepatitis C. Aliment Pharmacol Ther 2003;17:687-94.
15. Wong JB, Neven F. Cost-effectiveness of peginterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin as initial treatment of chronic hepatitis C in Belgium. Acta GastroEnterol Belg 2002;65:110-11.
16. Salomon JA, Weinstein MC, Hammitt JK, et al. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA 2003;290:228-37.
17. Hadziyannis SJ, Sette H, Jr., Morgan TR, et al. Peginterferon-alfa-2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-55.
18. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus Infection. N Engl J Med 2002;347:975-82.
19. Ferenci P, Shiffman ML, Fried MW, et al. Early prediction of response to 40 kDa peginterferon alfa-2a (Pegasys) plus ribavirin (RBV) in patients with chronic hepatitis C (CHC). Hepatology 2001;34:351A. (abstract).
20. Data on File (Reference no. 167-076), Hoffmann-La Roche Inc., Nutley, NJ.
21. Fattovich G, Guistina G, Degas F. Morbidity and mortality in compensated cirrhosis type C: A retrospective follow up study of 384 patients. Gastroenterology 1997;112:463-72.
22. Ascher NL, Lake JR, Emond J, et al. Liver transplantation for hepatitis C virus-related cirrhosis. Hepatology 1994;20:245-75.
23. Detre KM, Belle SH, Lomardero M. Liver transplantation for chronic viral hepatitis. Viral Hepat Rev 1996;2:2219-228.
24. Kilpe VE, Krakauer H, Wren RE. An analysis of liver transplantation experience from 37 transplant centers as reported to Medicare. Transplantation 1993;56:554-61.
25. National Center for Health Statistics. Vital statistics of the United States, 1997. Volume 2, Mortality, Part A. Washington, DC: Public Health Service, 1998.
26. Younossi Z, McCormick M, Boparai N, et al. Assessment of utilities and health-related quality of life in patients with chronic liver disease. Am J Gastroenterol 2001;96:579-83.
27. Kim WR, Poterucha JJ, Hermans JE, et al. Cost-effectiveness of 6 and 48 weeks of interferon-alpha therapy for chronic hepatitis C. Ann Intern Med 1997;127:866-74.
28. Bennett WG, Inoue Y, Beck JR, et al. Estimates of the cost-effectiveness of a single course of interferon alpha2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997;127:855-65.
29. Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996.
30. Stein K, Rosenburg W, Wong J. Cost effectiveness of combination therapy for hepatitis C: A decision analytic model. Gut 2002;50:253-8.
31. Sennfalt K, Reichard O, Hultkrantz R, et al. Cost-effectiveness of interferon alfa-2b with and without ribavirin as therapy for chronic hepatitis C in Sweden. Scand J Gastroenterol 2001;36:870-6.
32. Buti M, Casado MA, Fosbrook L, et al. Cost-effectiveness of combination therapy for naïve patients with chronic hepatitis C. J Hepatol 2000;33:651-8.
33. Wong JB, Poynard T, Ling MH, et al. and the International Hepatitis Interventional Therapy Group. Cost-effectiveness of 24 or 48 weeks of interferon alpha-2b alone or with ribavirin as initial treatment of chronic hepatitis C. Am J Gastroenterol 2000;95:1524-30.
34. Swain M, Lai M-Y, Shiffman ML, et al. Treatment of chronic hepatitis C patients with peginterferon alfa-2a (40KD) (Pegasys®) alone or in combination with ribavirin (Copegus®) results in long-lasting sustained virological responses. J Hepatol 2003;39(suppl 2):175.
35. Freeman AJ, Dore GJ, Law MG, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001;34:809-15.